Literature DB >> 12738624

Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study.

Kim van der Zander1, Alphons J H M Houben, Leo Hofstra, Abraham A Kroon, Peter W de Leeuw.   

Abstract

Brain natriuretic peptide (BNP) is a cardiac hormone with natriuretic activity. The aim of this study was to investigate the cardiovascular effects of pathophysiological levels of BNP on central hemodynamics, cardiac function, renal hemodynamics and function, and microvascular hemodynamics in healthy subjects. In this double-blind, placebo-controlled crossover study, we intravenously infused BNP (4 pmol. kg-1. min-1) or placebo for 1 h on two separate days in 12 healthy subjects (mean age, 60 +/- 5 yr). Nailfold and conjunctival capillary density, finger-skin (thermoregulatory) microvascular blood flow, and cardiac output were studied before and after infusion using intravital videomicroscopy, laser-Doppler fluxmetry, and echocardiography, respectively. Furthermore, during infusion, we measured the effective renal plasma flow and glomerular filtration rate using p-aminohippurate and inulin clearances. Blood pressure and heart rate were monitored for all measurements. Compared with placebo, BNP significantly decreased stroke volume with a tendency to decrease cardiac output. With subjects in the sitting position, mean arterial pressure decreased and heart rate increased after BNP infusion, whereas with subjects in the supine position, these variables remained unchanged. BNP increased natriuresis, diuresis, glomerular filtration rate, filtration fraction, and filtered load of Na+ compared with placebo, whereas effective renal plasma flow did not change. BNP did not affect the microvascular capillary density of conjunctiva and skin, microvascular blood flow, total skin oxygen capacity, and postocclusive recruitment. These results suggest that BNP has predominantly central and renal hemodynamic effects; however, it does not influence peripheral microcirculation in skin and conjunctiva.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12738624     DOI: 10.1152/ajpheart.00085.2003

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  14 in total

Review 1.  Soluble guanylate cyclase modulators in heart failure.

Authors:  Veselin Mitrovic; Ana Jovanovic; Stefan Lehinant
Journal:  Curr Heart Fail Rep       Date:  2011-03

Review 2.  Nesiritide for acute decompensated heart failure: does the benefit justify the risk?

Authors:  Jonathan Sackner-Bernstein; Keith D Aaronson
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

Review 3.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Role of guanylate cyclase modulators in decompensated heart failure.

Authors:  Veselin Mitrovic; Adrian F Hernandez; Markus Meyer; Mihai Gheorghiade
Journal:  Heart Fail Rev       Date:  2009-12       Impact factor: 4.214

Review 5.  Role of Angiotensin Receptor-Neprilysin Inhibition in Heart Failure.

Authors:  Stuart B Prenner; Sanjiv J Shah; Clyde W Yancy
Journal:  Curr Atheroscler Rep       Date:  2016-08       Impact factor: 5.113

6.  B-type natriuretic peptide (BNP) affects the initial response to intravenous glucose: a randomised placebo-controlled cross-over study in healthy men.

Authors:  B B Heinisch; G Vila; M Resl; M Riedl; B Dieplinger; T Mueller; A Luger; G Pacini; M Clodi
Journal:  Diabetologia       Date:  2011-12-13       Impact factor: 10.122

7.  AlbuBNP, a recombinant B-type natriuretic peptide and human serum albumin fusion hormone, as a long-term therapy of congestive heart failure.

Authors:  Wei Wang; Ying Ou; Yanggu Shi
Journal:  Pharm Res       Date:  2004-11       Impact factor: 4.200

8.  Long-term effects of B-type natriuretic peptide infusion after acute myocardial infarction in a rat model.

Authors:  Isaac George; Steve Xydas; Stefan Klotz; Ilan Hay; Chuck Ng; Jonathan Chang; Kai Xu; Zhihe Li; Andrew A Protter; Ed X Wu; Mehmet C Oz; Jie Wang
Journal:  J Cardiovasc Pharmacol       Date:  2010-01       Impact factor: 3.105

9.  Differential associations between renal function and "modifiable" risk factors in patients with chronic heart failure.

Authors:  Tom D J Smilde; Kevin Damman; Pim van der Harst; Gerjan Navis; B Daan Westenbrink; Adriaan A Voors; Frans Boomsma; Dirk J van Veldhuisen; Hans L Hillege
Journal:  Clin Res Cardiol       Date:  2008-10-31       Impact factor: 5.460

10.  Brain natriuretic peptide in pulmonary arterial hypertension: biomarker and potential therapeutic agent.

Authors:  Brian Casserly; James R Klinger
Journal:  Drug Des Devel Ther       Date:  2009-12-29       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.